Innogen · People · Innogen Associates
Dr Mike Capaldi

CEO, Sunergos Innovations

Mike.Capaldi@sunergosinnovations.com

+44 (0)131 242 9251

Sunergos Innovations
47 Little France Crescent
Edinburgh
EH16 4TJ

uk.linkedin.com/pub/michael-capaldi/2/38/932

Dr. Mike Capaldi joined Edinburgh BioQuarter as Director in 2010 before founding Sunergos Innovations in October 2015. His career started as a post-doctoral researcher at the Royal Postgraduate Medical School, London but in 1984 he moved into industry, taking up an R&D post with the Swiss pharmaceutical company, Ciba Geigy (now Novartis). In 1987 he moved into sales and marketing at SmithKline & French (now GSK) where he ended up running the UK vaccine business. He has worked both at home and abroad (USA and Europe) serving as an executive director on the Boards of both publically listed and private companies including Nycomed Amersham plc, Core Group plc, Oxford Asymmetry plc, Synaptica Ltd, Scancell plc, Hunter-Fleming Ltd and CMP Therapeutics Ltd (in the latter four companies as CEO). Dr Capaldi is also currently a non-executive director of Stealthyx Therapeutics Ltd, Roslin Cells, Synaptica Ltd and Support4Bio Ltd.

Mike has extensive experience of raising capital from private and public markets having helped to raise over $60M since 1997 including an IPO of Core Group plc on the London Stock Exchange. He also has extensive M&A experience most recently having completed the sale of Hunter-Fleming to Newron Pharmaceuticals in 2008. He joined Edinburgh BioQuarter as Director in early 2010.